Clinical effectiveness of house dust mite immunotherapy in  mono- versus poly-sensitised patients with allergic rhinitis:  a systematic review and meta-analysis

Kim, Jin Youp; Hwang, Doyeon; Jang, Mijung; Rhee, Chae Seo; Han, Doo Hee

doi:10.4193/rhin20.588

Cited by 8 publications

(17 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since HDM is the only tablet approved for patients with non‐seasonal AR, data regarding polysensitized patients is important. Kim et al 2661 . reported a meta‐analysis of HDM AIT in mono‐ or polysensitized patients.…”

Section: Managementmentioning

confidence: 99%

“…Since 2017, numerous SRMAs were identified for SLIT tablets (Table XI.D.6.a.‐1). Eight reported both aqueous and tablet SLIT, 2426,2438,2636,2637,2644,2661–2663 six presented aqueous and tablet SLIT separately, 2438,2550,2638,2639,2664,2665 and nine reported on tablet SLIT alone 1982,1986,1995,2532,2636,2640,2646,2651,2672 . All studies reported outcomes for HDM, grass pollen, and/or ragweed pollen.…”

Section: Managementmentioning

confidence: 99%

“…While single allergen SLIT has been shown to be effective in both monosensitized and polysenstized patients, 2661,2668,2671 there is equivocal evidence on added benefit of multi‐allergen immunotherapy in the polyallergic patient. This is pertinent to tablet SLIT as well because of the limited number of antigens available as tablets.…”

Section: Managementmentioning

confidence: 99%

See 2 more Smart Citations

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

153

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Section: Managementmentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

153

View full text Add to dashboard Cite

show abstract

“…A meta-analysis study of HDM AIT in mono and poly-sensitized patients with AR found no significant differences in the nasal symptom score, medication score, or quality of life between the groups. The study concluded that single-allergen AIT using HDM was clinically effective for both mono and poly-sensitized AR patients ( 152 ). Component-resolved diagnosis is essential for avoiding the inclusion of irrelevant allergens in mixed shots.…”

Section: The Efficacy In Armentioning

confidence: 99%

Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?

et al. 2021

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an IgE-mediated disease that is characterized by Th2 joint inflammation. Allergen-specific immunotherapy (AIT) is indicated for AR when symptoms remain uncontrolled despite medication and allergen avoidance. AIT is considered to have been effective if it alleviated allergic symptoms, decreased medication use, improved the quality of life even after treatment cessation, and prevented the progression of AR to asthma and the onset of new sensitization. AIT can be administered subcutaneously or sublingually, and novel routes are still being developed, such as intra-lymphatically and epicutaneously. AIT aims at inducing allergen tolerance through modification of innate and adaptive immunologic responses. The main mechanism of AIT is control of type 2 inflammatory cells through induction of various functional regulatory cells such as regulatory T cells (Tregs), follicular T cells (Tfr), B cells (Bregs), dendritic cells (DCregs), innate lymphoid cells (IL-10+ ILCs), and natural killer cells (NKregs). However, AIT has a number of disadvantages: the long treatment period required to achieve greater efficacy, high cost, systemic allergic reactions, and the absence of a biomarker for predicting treatment responders. Currently, adjunctive therapies, vaccine adjuvants, and novel vaccine technologies are being studied to overcome the problems associated with AIT. This review presents an updated overview of AIT, with a special focus on AR.

show abstract

“…These inflammatory factors further promote B cells to secrete antigen-specific IgE (sIgE). When the allergen restimulates the immune process of the body, sIgE binds quickly to the allergen epitope and crosslink occurs, which makes mast cells degranulate and release allergic and inflammatory mediators, damage nasal mucosa and lead to AR [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of Loratadine Tablets in Combination with Other Drugs on Nasal Physiological Function and T Lymphocyte Subsets in Patients with Allergic Rhinitis

Zhang

Cheng

Luo

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

Objective. To investigate the effects of loratadine tablets in combination with other drugs on nasal physiological function and T lymphocyte subsets in patients with allergic rhinitis (AR). Methods. A total of 120 AR patients treated in our hospital from February 2018 to February 2021 were randomly divided into control group and research group. The control group was given mometasone furoate nasal spray combined with loratadine tablets, while the research group was given budesonide combined with loratadine. The efficacy, duration of clinical symptom remission, immune function indicators, T lymphocyte subset, nasal physiological function, and incidence of adverse reactions were compared between the two groups. Results. The efficacy results of the two groups showed that the effective rate of the research group was 96.67%, while the effective rate of the control group was 83.33%. The effective rate in the research group was higher compared to the control group (χ2: 5.925 P < 0.05 ). The results of clinical symptom relief time showed that the clinical symptom relief time of nasal congestion, itching, runny nose, and sneezing in the research group was lower than that in the control group, and the difference was statistically significant ( P < 0.05 ). The results of the comparison of immune function indicators showed that the IL-6, IL-8, and IgE of the research group were lower than those of the control group, while the Th1/Th2 of the research group were higher than those of the control group. There were no statistically significant differences in T lymphocyte subsets before nursing, but after treatment, the T lymphocyte subsets of the two groups decreased, and the level of CD3+, CD4+, CD8+, CD4+, and CD4+/CD8+ lymphocytes in the research group was lower than that of the control group, and the difference was statistically significant ( P < 0.05 ). Before treatment, there exhibited no significant difference in nasal physiological function, but after treatment, the nasal physiological function of the two groups was enhanced, and the MTT, NR, and MCR of the research group were lower than those of the control group, and the difference was statistically significant ( P < 0.05 ). Finally, the incidence of adverse reactions in the research group was lower compared to the control group, and the difference was statistically significant ( P < 0.05 ). Conclusion. Budesonide and loratadine are effective in improving patient efficacy, T lymphocyte subsets, and nasal physiological function, and are safer.

show abstract

Clinical effectiveness of house dust mite immunotherapy in mono- versus poly-sensitised patients with allergic rhinitis: a systematic review and meta-analysis

Cited by 8 publications

References 40 publications

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?

Effect of Loratadine Tablets in Combination with Other Drugs on Nasal Physiological Function and T Lymphocyte Subsets in Patients with Allergic Rhinitis

Contact Info

Product

Resources

About